In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinical isolates of Candida spp.

Peptides

Volumn 32, Issue 1, 2011, Pages 99-103

  Kamysz, E ^a   Simonetti, O ^b   Cirioni, O ^b   Arzeni, D ^b   Ganzetti, G ^b   Campanati, A ^b   Giacometti, A ^b   Gabrielli, E ^b   Silvestri, C ^b   Kamysz, W ^c   Offidani, A ^b   Barchiesi, F ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF GDA SK   (Poland)

Author keywords

Amphotericin B; Candida spp.; Caspofungin; Fluconazole; In vitro; PAL Lys Lys NH2; Synergy

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; LYSINE; PALMITOYL LYSINE LYSINE NH2; UNCLASSIFIED DRUG;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; ECHINOCANDINS; FLUCONAZOLE; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS;

CANDIDA; CANDIDA ALBICANS;

EID: 78650577384     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.10.022     Document Type: Article

References (37)

1. A. Avrahami, and Y. Shai A new group of antifungal and antibacterial lipopeptides derived from non membrane active peptides conjugated to palmitic acid J Biol Chem 279 2004 12277 12285
2. A. Avrahami, and Y. Shai Bestowing antifungal and antibacterial activities by lipophilic acid conjugation to d,l-amino acid-containing antimicrobial peptides: a plausible mode of action Biochemistry 42 2003 14946 14956
3. J.W. Baddley, and P.G. Pappas Antifungal combination therapy: clinical potential Drugs 65 2005 1461 1480
4. F. Barchiesi, D. Arzeni, Greganti, A. Marigliano, S. Tomassetti, and S. Spreghini Fluconazole susceptibility of Candida spp. isolates collected over nine years in a Teaching Hospital of Ancona, Italy J Chemother 19 2007 58 61
5. F. Barchiesi, A. Giacometti, O. Cirioni, D. Arzeni, C. Silvestri, and W. Kamysz In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH2 alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans Peptides 28 8 2007 1509 1513 (Pubitemid 47247967)
6. F. Barchiesi, E. Spreghini, S. Tomassetti, D. Giannini, and G. Scalise Caspofungin in combination with Amphotericin B against Candida parapsilosis Antimicrob Agents Chemother 51 2007 941 945
7. F. Barchiesi, E. Spreghini, S. Tomassetti, D. Giannini, and G. Scalise Comparison of fungidal activities of caspofungin and amphotericin B against Candida glabrata Antimicrob Agents Chemother 49 12 2005 4989 4992 (Pubitemid 41778910)
8. O. Cirioni, A. Giacometti, R. Ghiselli, W. Kamysz, C. Silvestri, and F. Orlando The lipopeptides Pal-Lys-Lys-NH(2) and Pal-Lys-Lys soaking alone and in combination with intraperitoneal vancomycin prevent vascular graft biofilm in a subcutaneous rat pouch model of staphylococcal infection Peptides 28 6 2007 1299 1303
9. C.J. Clancy, H. Huang, S. Cheng, H. Derendorf, and Nguyen MH Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments Antimicrob Agents Chemother 50 7 2006 2569 2572
10. A.J. De Lucca, and T.J. Walsh Antifungal peptides: novel therapeutic compounds against emerging pathogens Antimicrob Agents Chemother 43 1999 1 11
11. D.W. Denning Echinocandin antifungal drug Lancet 362 2003 1142 1151
12. G. Di Bonaventura, I. Spedicato, C. Picciani, D. D'Antonio, and R. Piccolomini In vitro pharmacodynamic characteristics of amphotericin B, caspofungin fluconazole and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies Antimicrob Agents Chemother 48 2004 4453 4456
13. A. Espinel-Ingroff Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi Rev Iberoam Micol 25 2008 101 106
14. M.E. Falagas, K.E. Apostolou, and V.D. Pappas Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies Eur J Clin Microbiol Infect Dis 25 2006 419 425
15. G.B. Fields, and R.L. Noble Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl-amino acids Int J Pept Protein Res 35 1990 161 214
16. R. Ghiselli, O. Cirioni, A. Giacometti, F. Mocchegiani, F. Orlando, and C. Bergnach Effects of the antimicrobial peptide BMAP-27 in a mouse model of obstructive jaundice stimulated by lipopolysaccharide Peptides 27 2006 2592 2599
17. G.M. González, M. Elizondo, and J. Ayala Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004-2007) surveillance study J Clin Microbiol 46 9 2008 2902 2905
18. R.E. Hancock Cationic peptides: effectors in innate immunity and novel antimicrobials Lancet Infect Dis 1 3 2001 156 164
19. R.E. Hancock, and D.S. Chapple Peptide antibiotics Antimicrob Agents Chemother 43 6 1999 1317 1323
20. P.S. Hiemstra, B.A. Fernie-King, J. McMichael, P.J. Lachmann, and J.M. Sallenave Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics Curr Pharm Des 10 23 2004 2891 2905
21. M.D. Johnson, C. MacDougall, L. Ostrosky-Zeichner, J.R. Perfect, and J.H. Rex Combination antifungal therapy Antimicrob Agents Chemother 48 2004 693 715
22. K.S. Kim, and B.F. Anthony Importance of bacterial growth phase in determining minimal bactericidal concentration of penicillin and methicillin Antimicrob Agents Chemother 42 1981 1075 1077
23. A. Makovitzki, D. Avrahami, and Y. Shai Ultrashort antibacterial and antifungal lipopeptides Proc Natl Acad Sci U S A 24 103(43) 2006 15997 16002
24. A. Makovitzki, and Y. Shai Ph-dependent antifungal lipopeptides and their plausible mode of action Biochemistry 44 2005 9775 9784
25. A. Malina, and Y. Shay Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide Biochem J 390 2005 695 702
26. R.C. Moellering Principles of anti-infective therapy G.L. Mandell, J.E. Bennett, R. Dolin, Principles and practice of infectious diseases 1995 Churchill Livingstone Edinburgh 199 211
27. J. Mora-Duarte, R. Betts, R.C. Rotstein, A.L. Colombo, and J. Thompson-Moya Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
28. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast, 2nd ed. Approved standard M-27-A2. Antimicrob Agents Chemother. Wayne, PA: National Committee for Clinical Laboratory Standards; 2003.
29. P.G. Pappas, J.H. Rex, J. Lee, L.A. Larsen, and W. Powederly A prospective observational study of candidemia: epidemiology, therapy, and influencens on mortality in hospitalized adult and pediatric patients Clin Infect Dis 37 2003 634 643
30. M.A. Pfaller, D.J. Diekema, S.A. Messer, R.J. Hollis, and R.N. Jones In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3.959 clinica isolates of Candida spp., including 157fluconazole-resistant isolates Antimicrob Agents Chemother 47 2003 1068 1071
31. M.A. Pfaller, D.J. Sheehan, and J.H. Rex Determination of fungicidal activities against yeasts and moulds: lessons learned from bactericidal testing and the need for standardization Clin Microbiol Rev 17 2004 268 280
32. J.H. Powers Development of drugs for antimicrobial-resistant pathogens Curr Opin Infect Dis 16 6 2003 547 551
33. J.H. Rex, J.R. Wingard, R. Wenzel, R. Herbrecht, J. Sobel, and J.E. Edwards The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview Clin Infect Dis 39 Suppl 4 2004 S165 S169
34. O. Simonetti, D. Arzeni, G. Ganzetti, C. Silvestri, O. Cirioni, and E. Gabrielli In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes Br J Dermatol 161 2 2009 249 252
35. B.J. Spellberg, S.G. Filler, and J.E. Edwards Current treatment strategies for disseminated candidiasis Clin Infect Dis 42 2006 244 251
36. E. Tuomanen, R. Cozens, W. Tosch, O. Zak, and A. Tomasz The rate of killing of Esherichia coli is strictly proportional to the rate of bacterial growth J Gen Microbiol 132 1986 1297 1304
37. S.B. Wey, M. Mori, M.A. Pfaller, R.F. Woolson, and R.P. Wenzel Hospital-acquired candidemia: the attributable mortality and excess length of stay Arch Intern Med 148 1988 2642 2645